Several diseases that interfere with the differential diagnosis of inflammatory bowel disease

Published on Aug. 25, 2022Total Views: 1860 timesTotal Downloads: 1389 timesDownloadMobile

Author: Xia TIAN Zheng HAN Xiao-Dong HUANG

Affiliation: Department of Gastroenterology, Wuhan Third Hospital, Wuhan 430060, China

Keywords: Inflammatory bowel disease Infectious enteritis Non-infectious bowel disease

DOI: 10.12173/j.issn.1004-5511.202203049

Reference: Tian X, Han Z, Huang XD. Several diseases that interfere with the differential diagnosis of inflammatory bowel disease[J]. Yixue Xinzhi Zazhi, 2022, 32(4): 281-288. DOI: 10.12173/j.issn.1004-5511.202203049.[Article in Chinese]

  • Abstract
  • Full-text
  • References

A variety of diseases have clinical symptoms, endoscopic manifestations and histo-pathology which are similar to inflammatory bowel diseases (IBD). These can affect its diagnosis and differential diagnosis, and have attracted the attention of doctors in recent years. This article expounds the key points of the related diseases that interfere with the diagnosis of IBD so as to help clinicians im-prove the diagnosis rate and reduce its missed and misdiagnosis diagnosis rates.

Please download the PDF version to read the full text: download

1.胡仁伟, 欧阳钦, 陈曦, 等. 近15年我国炎症性肠病文献分析 [J]. 胃肠病学 , 2007, 12(2): 74-77. [Hu RW, Ouyang Q, Chen X, et al. Analysis of the articles of inflammatory bowel disease in the literature of china in recent fifteen years[J]. Chinese Journal of Gastroenterology, 2007, 12(2): 74-77.] DOI: 10.3969/j.issn.1008-7125. 2007.02.004.

2.Nuij VJ, Zelinkova Z, Rijk MC, et al. Phenotype of inflammatory bowel disease at diagnosis in the Netherlands: a population-based inception cohort study (the Delta Cohort)[J]. Inflamm Bowel Dis, 2013, 19: 2215-2222. DOI: 10.1097/MIB.0b013e3182961626.

3.Magro F, Langner C, Driessen A, et al. European consensus on the histopathology of inflammatory bowel disease[J]. J Crohns Colitis, 2013, 7: 827-851. DOI: 10.1016/j.crohns. 2013.06.001.

4.Prenzel F, Uhlig HH. Frequency of indeterminate colitis in children and adults with IBD-a meta analysis[J]. J Crohns Colitis, 2009, 3(4): 277-281. DOI: 10.1016/j.crohns. 2009.07.001. 

5.Van Assche G, Dignass A, Panes J, et al. The second European evidence-based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis[J]. J Crohns Colitis, 2010, 4(1): 7-27. DOI: 10.1016/j.crohns.2009.12.003. 

6.Annese V, Daperno M, Rutter MD, et al. European evidence based consensus for endoscopy in inflammatory bowel disease[J]. J Crohns Colitis, 2013, 7(12): 982-1018. DOI: 10.1016/j.crohns.2013.09.016.

7.Netz U, Carter J, Eichenberger MR, et al. Plasma microRNA profile differentiates Crohn's colitis from ulcerative colitis[J]. Inflamm Bowel Dis, 2017, 24(1): 159-165. DOI: 10.1093/ibd/izx009.

8.Quaglio AEV, Santaella FJ, Rodrigues MAM, et al. MicroRNAs expression influence in ulcerative colitis and Crohn's disease: a pilot study for the identification of diagnostic biomarker[J], World J Gastroenterol, 2021, 27(45): 7801-7812. DOI: 10.3748/wjg.v27.i45.7801. 

9.Morgan OW, Rodrigues B, Elston T, et a1. Clinical severity of Clostridium difficile PCR ribotype 027: a cage-case study[J]. PLoS One, 2008, 3(3): e1812. DOI: 10.1371/journal.pone.0001812.

10.Lamps LW. Update on infectious enterocolitides and the diseases that they mimic[J]. Histopathology, 2015, 66(1): 3-14. DOI: 10.1111/his.12582. 

11.Lamps LW, Madhusudhan KT, Greenson JK, et  al. The role of Yersinia enterocolitica and Yersinia pseudotuberculosis in granulomatous appendicitis: a histologic and molecular study[J]. Am J Surg Pathol, 2001, 25(4): 508-515. DOI: 10.1097/00000478-200104000-00011. 

12.Jodorkovsky D, Young Y, Abreu MT. Clinical outcomes of patients with ulcerative colitis and co-existing Clostridium difficile infection[J]. Dig Dis Sci, 2010, 55(2): 415-420. DOI: 10.1007/s10620-009-0749-9. 

13.Schneeweiss S, Korzenik J, Solomon DH, et al. Infliximab and otherimmunomodulating drugs in patients with inflammatory bowel diseaseand the risk of serious bacterial infections[J]. Aliment Pharmacol Ther, 2009, 30(3): 253-264. DOI: 10.1111/j.1365-2036.2009.04037.x.

14.Ben-Horin S, Margalit M, Bossuyt P, et al. Prevalence and clinical impact of endoscopic pseudomembranes in patients with inflammatory bowel disease and Clostridium difficile infection[J]. J Crohns Colitis, 2010, 4(2): 194-198. DOI: 10.1016/j.crohns.2009.11.001.

15.Kedia S, Das P, Madhusudhan KS, et al. Differentiating Crohn's disease from intestinal tuberculosis[J]. World J Gastroenterol, 2019, 25(4): 418-432. DOI: 10.3748/wjg.v25.i4.418.

16.Bae JH, Park SH, Ye BD, et al. Development and validation of a novel prediction model for differential diagnosis between Crohn's disease and intestinal tuberculosis[J]. Inflamm Bowel Dis, 2017, 23(9): 1614-1623. DOI: 10.1097/MIB.0000000000001162. 

17.Du J, Ma YY, Xiang H, et al. Confluent granulomas and ulcers lined by epithelioid histiocytes: new ideal method for differentiation of ITB and CD? A meta analysis[J]. PLoS One, 2014, 9(10): e103303. DOI: 10.1371/journal.pone.0103303.

18.Kumar S, Bopanna S, Kedia S, et al. Evaluation of Xpert MTB/RIF assay performance in the diagnosis of abdominal tuberculosis[J]. Intest Res, 2017, 15(2): 187-194. DOI: 10.5217/ir.2017.15.2.187.

19.Limsrivilai J, Shreiner AB, Pongpaibul A, et al. Meta-analytic bayesian model for differentiating intestinal tuberculosis from Crohn's disease[J]. Am J Gastroenterol, 2017, 112(3): 415-427. DOI: 10.1038/ajg.2016.529.

20.Sharma SK, Ryan H, Khaparde S, et al. Index-TB guidelines: guidelines on extrapulmonary tuberculosis for India[J]. Indian J Med Res, 2017, 145(4): 448-463.DOI: 10.4103/ijmr.IJMR_1950_16.

21.Tiwari V, Kedia S, Garg SK, et al. CD4+ CD25+ FOXP3+ T cell frequency in the peripheral blood is a biomarker that distinguishes intestinal tuberculosis from Crohn's disease[J]. PLoS One, 2018, 13(2): e0193433. DOI: 10.1371/journal.pone.0193433.

22.You DM, Johnson MD. Cytomegalovirus infection and the gastrointestinal tract[J]. Curr Gastroenterol Rep, 2012, 14(4): 334-342. DOI: 10.1007/s11894-012-0266-4.

23.Römkens TE, Bulte GJ, Nissen LH, et al. Cytomegalovirus in inflammatory bowel disease: a systematic review[J]. World J Gastroenterol, 2016, 22(3): 1321-1330. DOI: 10.3748/wjg.v22.i3.1321.

24.Weng MT, Tung CC, Lee YS, et al. Cytomegalovirus colitis in hospitalized inflammatory bowel disease patients in Taiwan: a referral center study[J]. BMC Gastroenterol, 2017, 17(1): 28. DOI: 10.1186/s12876-017-0586-9.

25.Mourad FH, Hashash JG, Kariyawasam VC,et al. Ulcerative colitis and cytomegalovirus infection: from A to Z[J]. J Crohns Colitis, 2020, 14(8): 1162-1171. DOI: 10.1093/ecco-jcc/jjaa036.

26.Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults[J]. Gut, 2019, 68(Suppl 3): s1-s106. DOI: 10.1136/gutjnl-2019-318484.

27.Pillet S, Pozzetto B, Roblin X. Cytomegalovirus and ulcerative colitis: place of antiviral therapy[J]. World J Gastroenterol, 2016, 22(6): 2030-2045. DOI: 10.3748/wjg.v22.i6.2030.

28.Wu S, He C, Tang TY, et al. A review on co-existent Epstein-Barr virus-induced complications in inflammatory bowel disease[J]. Eur J Gastroenterol Hepatol, 2019, 31(9): 1085-1091. DOI: 10.1097/MEG. 0000000000001474.

29.Liu R, Wang M, Zhang L, et al. The clinic opathologic features of chronic active Epstein-Barr virus infective enteritis. Modern pathology : an official journal of the United States and Canadian Academy of Pathology[J]. Mod Pathol, 2019, 32(3): 387-395. DOI: 10.1038/s41379-018-0144-1.

30.Xu W, Jiang X, Chen J, et al. Chronic active Epstein-Barr virus infection involving gastrointestinal tract mimicking inflammatory bowel disease[J]. BMC gastroenterology, 2020, 20(1): 257. DOI: 10.1186/s12876-020-01395-9.

31.Zhang B, Wang X, Tian X, et al. Chronic active epstein-barr virus-associated enteritis: CT findings and clinical manifestation[J]. Biomed Res Int, 2020, 2020: 2978410. DOI: 10.1155/2020/2978410.

32.Tanyuksel M, Petri WA Jr. Laboratory diagnosis of amebiasis[J]. Clin Microbiol Rev, 2003, 16(4): 713-729. DOI: 10.1128/CMR.16.4.713-729.2003.

33.Bercu TE, Petri WA, Behm JW. Amebic colitis: new insights into pathogenesis and treatment[J]. Curr Gastroenterol Rep, 2007, 9(5): 429-433. DOI: 10.1007/s11894-007-0054-8.

34.Hoentjen F, Rubin DT. Infectious proctitis: when to suspect it is not inflammatory bowel disease[J]. Dig Dis Sci, 2012, 57(2): 269-273. DOI: 10.1007/s10620-011-1935-0.

35.Assi MA, Sandid MS, Baddour LM, et al. Systemic histoplasmosis: a 15-year retrospective institutional review of 111 patients[J]. Medicine (Baltimore), 2007, 86(3): 162-169. DOI: 10.1097/md.0b013e3180679130.

36.Stanojevic GZ, Nestorovic MD, Brankovic BR, et al. Primary colorectal lymphoma: an overview[J]. World J Gastrointest Oncol, 2011, 3(1): 14-18. DOI: 10.4251/wjgo.v3.i1.14. 

37.Koch P, del VF, Berdel WE, et al. Primary gastrointestinal non-Hodgkin's lymphoma: I. Anatomic and histologic distribution, clinical features, and survival data of 371 patients registered in the German Multicenter Study GIT NHL 01/92[J]. J Clin Oncol, 2001, 19(18): 3861-3873. DOI: 10.1200/JCO.2001.19.18.3861.

38.Heise W. GI-lymphomas in immunosuppressed patients (organ transplantation; HIV)[J]. Best Pract Res Clin Gastroenterol, 2010, 24(1): 57-69. DOI: 10.1016/j.bpg. 2010.01.001.

39.Zhang TY, Lin Y, Fan R, et al. Potential model for differential diagnosis between Crohn's disease and primary intestinal lymphoma[J]. World J Gastroenterol, 2016, 22(42): 9411-9418. DOI: 10.3748/wjg.v22.i42.9411.

40.Chiu  KW, Changchien  CS, Chuah  SK, et al. Endoscopic and image features in primary gastro-intestinal lymphoma: a 7-year experience[J]. Hepatogastroenterology, 1995, 42(4): 367-370. DOI: 10.1002/hed.2880170416.

41.Ning L, Shan G, Sun Z, et al. Serum proteome profiles to differentiate Crohn disease from intestinal tuberculosis and primary intestinal lymphoma: a pilot study[J]. Medicine (Baltimore), 2019, 98(50): e18304. DOI: 10.1097/MD. 0000000000018304.

42.Kontogianni A, Delakidis S, Basioukas P, et al. Ischemic colitis: clinical, endoscopic and histologic spectrumof 254 cases[J]. Ann Gastroenterol, 2003, 16(4): 316-320.

43.Felicetti M, Treppo E, Posarelli C, et al. One year in review 2020: vasculitis[J]. Clin Exp Rheumatol, 2020, 124(2): 3-14.

44.Davatchi F. Behçet's disease[J]. Int J Rheum Dis, 2018, 21(12): 2057-2058. DOI: 10.1111/1756-185X.13465. 

45.Lamps LW. Infectious diseases of the lower gastrointestinal tract[J]. Surg Pathol Clin, 2010, 3(2): 297-326. DOI: 10.1016/j.path.2010.05.009. 

46.Valenti S, Gallizzi R, De Vivo D, et al. Intestinal Behçet and Crohn's disease: two sides of the same coin[J]. Pediatr Rheumatol Online J, 2017, 15(1): 33. DOI: 10.1186/s12969-017-0162-4.

47.Skef W, Hamilton MJ, Arayssi T. Gastrointestinal Behçet's disease: a review[J]. World J Gastroenterol, 2015, 21(13): 3801-3812. DOI: 10.3748/wjg.v21.i13.3801.

48.Eckmann JD, Chedid V, Quinn KP, et al. De novo colitis associated with rituximab in 21 patients at a tertiary center[J]. Clin Gastroenterol Hepatol, 2020, 18: 252-253. DOI: 10.1016/j.cgh.2019.03.027. 

49.Katsinelos P, Christodoulou K, Pilpilidis I, et al. Colopathy associated with the systemic use of nonsteroidal antiinflammatory medications. An underestimated entity[J]. Hepatogastroenterology, 2002, 49(44): 345-358.

50.Price AB. Pathology of drug-associated gastrointestinal disease[J]. Br J Clin Pharmacol, 2003, 56(5): 477-482. DOI: 10.1046/j.1365-2125.2003.01980.x. 

51.Püspök A, Kiener HP, Oberhuber G. Clinical, endoscopic, and histologic spectrum of nonsteroidal anti-inflammatory drug-induced lesions in the colon[J]. Dis Colon Rectum, 2000, 43(5): 685-691. DOI: 10.1007/BF02235589.

52.Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline[J]. J Clin Oncol, 2018, 36(17): 1714-1768. DOI: 10.1200/JCO.2017.77.6385. 

53.Gecse KB, Vermeire S. Differential diagnosis of inflammatory bowel disease: imitations and complications[J]. Lancet Gastroenterol Hepatol, 2018, 3(9): 644-653. DOI: 10.1016/S2468-1253(18)30159-6. 

54.Ahishali  E, Uygur-Bayramiçli  O, Dolapçioğlu  C, et al. Chemical colitis due to glutaraldehyde: case series and review of the literature[J]. Dig Dis Sci, 2009, 54(12): 2541-2545. DOI: 10.1007/s10620-008-0630-2.

55.Stacey R, Green JT. Radiation-induced small bowel disease: latest developments and clinical guidance[J]. Ther Adv Chronic Dis, 2014, 5(1): 15-29. DOI: 10.1177/20406 22313510730.

56.Tabaja  L, Sidani  SM. Management of radiation proctitis[J]. Dig Dis Sci, 2018, 63(9): 2180-2188. DOI: 10.1007/s10620-018-5163-8. 

57.Marlicz W, Loniewski I, Grimes DS, et al. Nonsteroidal anti-inflammatory drugs, proton pump inhibitors, and gastrointestinal injury: contrasting interactions in the stomach and small intestine[J]. Mayo Clin Proc, 2014, 89(12): 1699-1709. DOI: 10.1016/j.mayocp.2014.07.015. 

58.Tominaga K, Kamimura K, Takahashi K, et al. Diversion colitis and pouchitis: a mini-review[J]. World J Gastroenterol, 2018, 24(16): 1734-1747. DOI: 10.3748/wjg.v24.i16.1734.  

59.Sharma P, Yadav S, Needham CM, et al. Sclerosing mesenteritis: a systematic review of 192 cases[J]. Clin J Gastroenterol, 2017, 10(2): 103-111. DOI: 10.1007/s12328-017-0716-5. 

60.Akram S, Pardi DS, Schaffner JA, et al. Sclerosing mesenteritis: clinical features, treatment, and outcome in ninety-two patients[J]. Clin Gastroenterol Hepatol, 2007, 5(5): 589-596. DOI: 10.1016/j.cgh.2007.02.032.